Caso Francesco, Costa Luisa, Del Puente Antonio, Di Minno Matteo Nicola Dario, Lupoli Gelsy, Scarpa Raffaele, Peluso Rosario
Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, and Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II of Naples, Italy.
Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II of Naples, Italy.
Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647.
Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients' quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.
脊柱关节炎是一组异质性的关节炎症性疾病，具有共同的遗传、临床和放射学特征。脊柱关节炎的治疗目标主要在于提高患者的生活质量、控制关节炎症、预防关节结构破坏以及维持患者的功能能力、自主性和社会参与度。其中，传统的改善病情抗风湿药物已被证明在治疗外周关节炎方面有效；此外，在过去十年中，生物疗法改善了脊柱关节炎的治疗方法。在轴性脊柱关节炎患者中，肿瘤坏死因子α抑制剂目前是传统非甾体抗炎药治疗失败患者的唯一有效疗法。本综述的目的是总结目前关于脊柱关节炎患者药物治疗方法的经验和证据。
